Download PDF
Exp Clin Endocrinol Diabetes 1992; 99(3): 151-153
DOI: 10.1055/s-0029-1211158
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Serum Levels of 1,25-(OH)2-Vitamin D are not Altered by Long-Term Supplementation with Alphacalcidol (1-OH-Vitamin D3)

A Double-Blind, Placebo-Controlled StudyL. Lind, B. Wengle, O. H. Sörensen, S. Ljunghall
  • Departments of Internal Medicine (Head: Prof. S. Ljunghall), University Hospital, Uppsala and Gävle Hospital and Department of Internal Medicine, Sundby Hospital, Copenhagen/Denmark
Further Information

Publication History

1992

Publication Date:
16 July 2009 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The endogenous production of 1,25-(OH)2-vitamin D has been estimated to be 1.5 µg daily. Despite the use of alphacalcidol (l,25-(OH)2-vitamin D) during more than a decade the long-term effects of the serum levels of 1,25-(OH)2-vitamin D have been poorly investigated. When 1 µg of alphacalcidol was given daily to 39 non-vitamin D deficient subjects in a double-blind, placebo-controlled study during 4 months no significant effects on the serum levels of 1,25-(OH)2-vitamin D or 25-(OH)-vitamin D were found. The treatment however induced a 50% increase in urinary excretion of calcium (p<0.01). In conclusion, long-term supplementation with a physiological dose of alphacalcidol does not influence the serum levels of 1,25-(OH)2-vitamin D, despite a marked effect on urinary calcium excretion.

Key words

Alphacalcidol - Calcitriol - Calcium - Parathyroid hormone